Zoetis Inc. (ZTS)

Market Cap	67.75B
Revenue (ttm)	9.39B
Net Income (ttm)	2.61B
Shares Out	443.18M
EPS (ttm)	5.82
PE Ratio	26.28
Forward PE	23.36
Dividend	$2.00 (1.31%)
Ex-Dividend Date	Jul 18, 2025

Volume	2,176,229
Open	154.98
Previous Close	156.40
Day's Range	151.61 - 155.38
52-Week Range	139.70 - 200.33
Beta	0.88
Analysts	Buy
Price Target	201.71 (+31.94%)
Earnings Date	Aug 5, 2025

About ZTS

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other ph...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 1, 2013
• Employees: 13,800
• Stock Exchange: NYSE
• Ticker Symbol: ZTS
• Website: https://www.zoetis.com

Financial Performance

In 2024, Zoetis's revenue was $9.26 billion, an increase of 8.33% compared to the previous year's $8.54 billion. Earnings were $2.49 billion, an increase of 6.06%.

Analyst Summary

According to 7 analysts, the average rating for ZTS stock is "Buy." The 12-month stock price target is $201.71, which is an increase of 31.94% from the latest price.

Price Target

$201.71

(31.94% upside)

Analyst Consensus: Buy